Clinical trial
Open Label, Phase I ZD6474 Head and Neck Cancer Study
NCT00450138 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00450138 |
|---|---|
| Title | Open Label, Phase I ZD6474 Head and Neck Cancer Study |
| Official title | An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug, Radiation |
| Interventions | ZD6474 (vandetanib), Cisplatin, Radiation |
| Enrollment | 48 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2011 |
| First posted | Mar 21, 2007 |
| Last update posted | Aug 29, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: